

Oncology Today with Dr Neil Love: Side Effects of Hormonal Therapy in Prostate Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following secondary hormonal therapies is more commonly associated with hypothyroidism in the management of prostate cancer?**
 - a. Apalutamide**
 - Abiraterone
 - Enzalutamide
- 2. Which of the following statements is true regarding relugolix, an oral LHRH antagonist, as it was compared to standard leuprolide for patients with advanced prostate cancer in the Phase III HERO trial?**
 - Relugolix was associated with a higher risk of major cardiovascular adverse events
 - Relugolix was associated with a lower risk of major cardiovascular adverse events**
- 3. What is the relative incidence of bone fractures observed with androgen receptor (AR)-targeted therapies, such as apalutamide or enzalutamide, with androgen deprivation therapy (ADT) compared to placebo with ADT for patients with nonmetastatic castration-resistant prostate cancer?**
 - Similar with both treatments
 - Lower with AR-targeted therapies
 - Higher with AR-targeted therapies**
- 4. Which of the following functionalities contributes to the mechanism of CNS toxicity observed with secondary hormonal therapies in patients with prostate cancer?**
 - Differential ability of the hormonal agents to cross the blood-brain barrier**
 - Similar ability of the hormonal agents to cross the blood-brain barrier